Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 16 Uterine Cervical Neoplasms 5 Stomach Neoplasms 5 Lung Neoplasms 5 Carcinoma, Transitional Cell 5 Carcinoma, Hepatocellular 5 Squamous Cell Carcinoma of Head and Neck 4 Sarcoma 4 Prostatic Neoplasms 4 Ovarian Neoplasms 4 Oropharyngeal Neoplasms 4 Esophageal Neoplasms 4 Cholangiocarcinoma 4 Urinary Bladder Neoplasms 3 Thyroid Neoplasms 3 Neuroendocrine Tumors 3 Neoplasm Metastasis 3 Multiple Myeloma 3 Lymphoma, Large B-Cell, Diffuse 3 Anus Neoplasms 3 Testicular Neoplasms 2 Solid Tumor 2 Pheochromocytoma 2 Paraganglioma 2 Pancreatic Neoplasms 2 Neoplasms 2 Mouth Neoplasms 2 Melanoma 2 Leukemia, Myeloid, Acute 2 Laryngeal Neoplasms 2

Interventions

Rituximab 45 Cyclophosphamide 32 Lenalidomide 24 fludarabine 20 zanubrutinib 13 venetoclax 12 obinutuzumab 12 orelabrutinib 11 fludarabine phosphate 10 Bendamustine Hydrochloride 10 Magnetic Resonance Spectroscopy 9 Whole-Body Irradiation 8 Prednisone 8 pirtobrutinib 7 ibrutinib 7 Vincristine 7 Specimen Handling 7 CT-P10 7 Mycophenolic Acid 6 Biopsy 6 Doxorubicin 5 tafasitamab 4 pembrolizumab 3 acalabrutinib 3 Tacrolimus 3 Sirolimus 3 Radiotherapy 3 Peripheral Blood Stem Cell Transplantation 3 Nivolumab 3 Melphalan 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, B-Cell, Marginal Zone × Fluorodeoxyglucose F18 × 1 year × Clear all

NCT06125028 2026-04-28

LYMFOR

Pentixapharm AG

Phase 3 Terminated

Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon ⚡